143 related articles for article (PubMed ID: 29927979)
1. A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent.
Thakar M; Hu Y; Morreale M; Lerner L; Ying Lin W; Sen R; Cai Y; Karunasena E; Thakar M; Saggi S; Keer H; Ahuja N
PLoS One; 2018; 13(6):e0199130. PubMed ID: 29927979
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells.
Gailhouste L; Liew LC; Hatada I; Nakagama H; Ochiya T
Cell Death Dis; 2018 May; 9(5):468. PubMed ID: 29700299
[TBL] [Abstract][Full Text] [Related]
3. DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications.
Wong KK
Cell Oncol (Dordr); 2020 Oct; 43(5):779-792. PubMed ID: 32504382
[TBL] [Abstract][Full Text] [Related]
4. A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells.
Kohi S; Sato N; Cheng XB; Koga A; Higure A; Hirata K
Clin Exp Metastasis; 2016 Mar; 33(3):225-30. PubMed ID: 26589701
[TBL] [Abstract][Full Text] [Related]
5. Minocycline and photodynamic priming significantly improve chemotherapy efficacy in heterotypic spheroids of pancreatic ductal adenocarcinoma.
Bano S; Alburquerque JQ; Roberts HJ; Pang S; Huang HC; Hasan T
J Photochem Photobiol B; 2024 Jun; 255():112910. PubMed ID: 38663337
[TBL] [Abstract][Full Text] [Related]
6. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin.
Kuang Y; El-Khoueiry A; Taverna P; Ljungman M; Neamati N
Mol Oncol; 2015 Nov; 9(9):1799-814. PubMed ID: 26160429
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition.
Huang MH; Chou YW; Li MH; Shih TE; Lin SZ; Chuang HM; Chiou TW; Su HL; Harn HJ
Pharmacol Res; 2019 Jan; 139():50-61. PubMed ID: 30385365
[TBL] [Abstract][Full Text] [Related]
8. Analyzing miRNAs in ductal adenocarcinomas of the pancreas.
Mees ST; Schleicher C; Mardin WA; Senninger N; Colombo-Benkmann M; Haier J
J Surg Res; 2011 Aug; 169(2):241-6. PubMed ID: 20080250
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo.
Ye J; Yuen SM; Murphy G; Xie R; Kwok HF
Eur J Pharm Sci; 2017 Dec; 110():62-69. PubMed ID: 28554668
[TBL] [Abstract][Full Text] [Related]
10. The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells.
Giannuzzo A; Pedersen SF; Novak I
Mol Cancer; 2015 Nov; 14():203. PubMed ID: 26607222
[TBL] [Abstract][Full Text] [Related]
11. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
[TBL] [Abstract][Full Text] [Related]
12. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
[TBL] [Abstract][Full Text] [Related]
13. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas.
Ohike N; Maass N; Mundhenke C; Biallek M; Zhang M; Jonat W; Lüttges J; Morohoshi T; Klöppel G; Nagasaki K
Cancer Lett; 2003 Sep; 199(2):193-200. PubMed ID: 12969792
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.
Li A; Omura N; Hong SM; Goggins M
Cancer Biol Ther; 2010 Feb; 9(4):321-9. PubMed ID: 20234167
[TBL] [Abstract][Full Text] [Related]
17. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H; Ning S; Nolley R; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Clin Epigenetics; 2017; 9():4. PubMed ID: 28149332
[TBL] [Abstract][Full Text] [Related]
18. Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma.
De Carvalho Fischer C; Hu Y; Morreale M; Lin WY; Wali A; Thakar M; Karunasena E; Sen R; Cai Y; Murphy L; Zahnow CA; Keer H; Thakar M; Ahuja N
Oncotarget; 2018 Apr; 9(27):19379-19395. PubMed ID: 29721210
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia.
Hirakawa T; Yashiro M; Doi Y; Kinoshita H; Morisaki T; Fukuoka T; Hasegawa T; Kimura K; Amano R; Hirakawa K
PLoS One; 2016; 11(8):e0159912. PubMed ID: 27487118
[TBL] [Abstract][Full Text] [Related]
20. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
